Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 28993052

Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet
Publication date
2017 Dec 2
First author
Kang YK

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Nat Rev Gastroenterol Hepatol. 2017 Dec;14(12):690. doi: 10.1038/nrgastro.2017.157.
    note
    Source null
    related pmid
    29094725
    relationship
    Comment in

Authors and identifiers

  1. name
    Kang YK
    type
    Author
  2. name
    Boku N
    type
    Author
  3. name
    Satoh T
    type
    Author
  4. name
    Ryu MH
    type
    Author
  5. name
    Chao Y
    type
    Author
  6. name
    Kato K
    type
    Author
  7. name
    Chung HC
    type
    Author
  8. name
    Chen JS
    type
    Author
  9. name
    Muro K
    type
    Author
  10. name
    Kang WK
    type
    Author
  11. name
    Yeh KH
    type
    Author
  12. name
    Yoshikawa T
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Kang YK
    type
    Author
  2. name
    Boku N
    type
    Author
  3. name
    Satoh T
    type
    Author
  4. name
    Ryu MH
    type
    Author
  5. name
    Chao Y
    type
    Author
  6. name
    Kato K
    type
    Author
  7. name
    Chung HC
    type
    Author
  8. name
    Chen JS
    type
    Author
  9. name
    Muro K
    type
    Author
  10. name
    Kang WK
    type
    Author
  11. name
    Yeh KH
    type
    Author
  12. name
    Yoshikawa T
    type
    Author
bibliography ids
  1. nci-bib-eb7bb19e2a75da98139bd25b
book metadata
content sha256
06602e5f015213331378e2cc0500b794aad5d93ff696907dc797dc68655a3e1a
document type
citation
dois
  1. 10.1016/S0140-6736(17)31827-5
electronic publication date
display
2017 Oct 6
precision
day
year
2017
evidence scope
bibliographic_metadata_only
id
pubmed:28993052
immutable id
pubmed:28993052@06602e5f015213331378e2cc0500b794aad5d93ff696907dc797dc68655a3e1a
journal
abbreviation
Lancet
issn electronic
1474-547X
issn print
0140-6736
issue
10111
name
Lancet (London, England)
nlm unique id
2985213R
pages
2461-2471
volume
390
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Nat Rev Gastroenterol Hepatol. 2017 Dec;14(12):690. doi: 10.1038/nrgastro.2017.157.
    note
    Source null
    related pmid
    29094725
    relationship
    Comment in
outcomes validated
false
pmid
28993052
provenance
batch id
fb25b16edcb1373b70c1
provider
NCBI PubMed ESummary
record sha256
d6ee55cff0e7c991129a3f474d53e7d9e1881782eceb3681dacb3e1e3e82e3e3
response sha256
182c99bf1974b58308315b66aa28d31c61e8fc31cf3de4cadb0340a4f6734c52
retrieved at
2026-09-09T23:47:28.490065+00:00
publication date
display
2017 Dec 2
precision
day
year
2017
publication types
  1. Clinical Trial, Phase III
  2. Journal Article
  3. Randomized Controlled Trial
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/28993052/
title
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial.

Preserved source evidence · Not medical advice